Background:  Catalyzes the second step of the reductive pyrimidine degradation, the reversible hydrolytic ring opening of dihydropyrimidines. Can catalyzes the ring opening of 5,6-dihydrouracil to N-carbamyl-alanine and of 5,6-dihydrothymine to N-carbamyl-amino isobutyrate. Tissue specificity:Liver and kidney. Involvement in disease: Defects in DPYS are the cause of dihydropyrimidinase deficiency (DHPD). DHPD is an autosomal recessive disorder characterized by dihydropyrimidinuria and associated with a variable clinical phenotype: epileptic or convulsive attacks, dysmorphic features and severe developmental delay, and congenital microvillous atrophy.

Description: Rabbit polyclonal to Dihydropyrimidinase

Immunogen: KLH conjugated synthetic peptide derived from Dihydropyrimidinase

Specificity:  ·Reacts with Human, Mouse and Rat.

·Isotype: IgG

Application:  ·Western blotting: 1/100-500. Predicted Mol wt: 54 kDa;

·Immunohistochemistry (Frozen/paraffin tissue section): 1/100-500;

·Immunocytochemistry: 1/100-200;

·ELISA: 1/500;

·Optimal working dilutions must be determined by the end user.